ELI LILLY CO

📅 Upcoming

🕒 Recent(90d)

News

• Lilly and Resilience invest $750M in diabetes and obesity drug device supply
  The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
  biospace · 6h ago
• Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
  Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.
  biospace · 7h ago
• Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
  Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
  fiercebiotech · 18h ago
• Capricor’s data clash and a fugitive in the C-suite
  Is the FDA taking inconsistent approaches to Duchenne drugs? And how will a new batch of drug executives shake up their companies? Find out on the latest episode of "The…
  stat · 1d ago
• J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
  The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
  biopharma_dive · 1d ago
• AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal
  More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its
  endpoints · 1d ago
• Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity
  Plus, news about Teva. 💶 Gerresheimer sells two subsidiaries to private equity: Gerresheimer is divesting its Centor and Primary Packaging Plastics (PPP) businesses to private equity firm Apax Par…
  endpoints · 1d ago
• J&J secures right to take the helm in up to $925M Sail CAR T pact
  As part of the collaboration, Johnson & Johnson will have an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion.
  biospace · 1d ago
• BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
  BMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.
  fiercebiotech · 1d ago
• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
  With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
  biospace · 1d ago